- Home
- TIL vs GLSI Comparison
TIL vs GLSI Comparison
Compare TIL & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- GLSI
- Stock Information
- Founded
- TIL 2018
- GLSI 2006
- Country
- TIL United States
- GLSI United States
- Employees
- TIL N/A
- GLSI N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- GLSI Health Care
- Exchange
- TIL Nasdaq
- GLSI Nasdaq
- Market Cap
- TIL 218.4M
- GLSI 197.1M
- IPO Year
- TIL 2021
- GLSI 2020
- Fundamental
- Price
- TIL $26.50
- GLSI $12.56
- Analyst Decision
- TIL Buy
- GLSI Strong Buy
- Analyst Count
- TIL 4
- GLSI 1
- Target Price
- TIL $100.33
- GLSI $38.00
- AVG Volume (30 Days)
- TIL 154.7K
- GLSI 25.6K
- Earning Date
- TIL 11-13-2024
- GLSI 11-26-2024
- Dividend Yield
- TIL N/A
- GLSI N/A
- EPS Growth
- TIL N/A
- GLSI N/A
- EPS
- TIL N/A
- GLSI N/A
- Revenue
- TIL N/A
- GLSI N/A
- Revenue This Year
- TIL N/A
- GLSI N/A
- Revenue Next Year
- TIL $2.64
- GLSI N/A
- P/E Ratio
- TIL N/A
- GLSI N/A
- Revenue Growth
- TIL N/A
- GLSI N/A
- 52 Week Low
- TIL $6.08
- GLSI $8.00
- 52 Week High
- TIL $92.00
- GLSI $21.44
- Technical
- Relative Strength Index (RSI)
- TIL 38.29
- GLSI 39.43
- Support Level
- TIL $24.31
- GLSI $11.89
- Resistance Level
- TIL $37.24
- GLSI $14.67
- Average True Range (ATR)
- TIL 4.02
- GLSI 0.93
- MACD
- TIL 0.26
- GLSI -0.08
- Stochastic Oscillator
- TIL 10.85
- GLSI 23.10
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.